BioNTech SE (BNTX) Tops Q4 EPS, Revenue

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. CVS

Go back to BioNTech SE (BNTX) Tops Q4 EPS, Revenue

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

March 27, 2023 6:45 AM EDT

Expanded and advanced oncology pipeline to 20 programs in 24 ongoing clinical trials including five ongoing randomized Phase 2 clinical trials; multiple trials with registrational potential expected to be initiated in 2023 and 2024Announced licensing agreement with OncoC4 to complement the Companys oncology portfolio with clinical stage next-generation immune checkpoint modulator; a randomized Phase 3 trial planned to start in 2023Initiated Phase 1 trials for four mRNA vaccine candidates in the infectious disease fieldApproximately 2 billion doses of COMIRNATY® invoiced in 2022, including approximately 550 million doses of Omicron-adapted bivalent COVID-19 vaccines Fourth quarter and full year... More